Clinical Trial Search

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment (Motor Scores). — 10; 5; 0; 1 participants

Primary: Area Under the Curve Following Administration of Oral Valacyclovir Suspension 20 mg/kg Every 8 Hours — 28.8 mgxh/l

Primary: Participants With Neurologic Impairment at 12 Months as Measured by a Bayley's Neuro-developmental Assessment.(Motor Scores) — 0; 3; 0; 0 Participants

Primary: Clearance (CL) — 0.278 L/h/kg

Primary: Number of Participants With Preterm Delivery — 100; 83; 247; 5407 Participants

Primary: Pharmacokinetics of Single Dose - Tmax — 1.00; 4; 1.02 hours

Primary: Mean Change in HIV-1 Levels in Plasma Between 34 and 38 Weeks Gestation — -0.53; 0.03 log10 copies/mL

Primary: Survival With no or Mild Neuropsychological Impairment at 12 Months After Initiation of Study Medication as Measured by the Mattis Dementia Rating Scale (MDRS) — 28; 34…

Primary: Number of Participants Experiencing Incidence of Nephrotoxicity, Defined as a Serum Creatinine ≥ 2 Times the Patient's Baseline — 2; 3 participants

Primary: Change in HCV RNA Viral Load — .24; .08 log(IU/mL) — p=0.05

Primary: Change in Best Ear Hearing Assessments at 6 Months. — 3; 5; 37; 36 participants

Primary: Time to Healing of Genital Lesions — 5.1; 6.0 Days

Primary: Ratio of Absolute Gene Expression of IFNG and IL5 in PBMCs Between 8 Weeks and Baseline — 10.073; 11.380; 10.711; 11.431 q-RT-PCR crossing threshold cycle (Ct)

Primary: Number of Neonatal Infections With a S. Aureus Strain That is Concordant to Parental S. Aureus Strain — 13; 29 neonatal S. aureus infections

Primary: Number of Participants With the Composite Primary Outcome — 46; 37 Participants — p=0.42

Primary: Zicam Was Compared to Placebo as a Treatment of Recurrent HSL From the Date and Time of the Initiation of Therapy Until the Date and Time of Resolution of the Lesion or…

Primary: Death or Candidiasis — 31; 37 participants

Primary: Percentage of Infants With Evidence of Neurological Dysfunction, Brain Injury and/or Abnormality. — 28 Participants

Primary: Number of Participants With Bacterial Vaginosis Recurrence — 8 Participants

Primary: Sensitivity of Detection of HSV DNA by GeneXpert PCR From Specimens Obtained From the Genital Tract of Non-pregnant Women in STI Clinics, as Compared With HSV Culture…

Primary: Number of Subjects With Serious Adverse Events (SAEs) — 71; 42; 37 Participants

Primary: Number of Subjects With Any Cytomegalovirus (CMV) Congenital Infection — 24; 20; 4; 58 Participants

Primary: Infant HIV Infection Status — 24; 11; 12 participants — p=.046

Primary: Proportion of Subjects Who Experience a New Cold Sore Outbreak That Proceeds to the Lesion Stage. Of Those Subjects That Take Study Medication (Experience a New Emerging…

Primary: Neonates With Seizure Cessation When Given Levetiracetam (40-60 mg/kg) as First Line Therapy Compared to Phenobarbital (20-40mg/kg) — 15; 24 Participants — p=<0.001

Primary: WIDEA Neurodevelopmental Outcome Score — 149.04; 162.46; 148.80; 151.89 score on a scale

Primary: Number of Ears That Had (1) Improved Hearing or no Change in Hearing (2) Worsened Hearing. — 27; 20; 1; 6 Ears — p=0.0859

Primary: Death or Moderate or Severe Disability — 29; 20 Participants

Primary: Percentage of Participants With Healing by Day 8 — 194 Participants

Primary: Duration of Episode (DOE) Was Measured in Hours (Using the Science 37 Platform), of a Single Treated Herpes Labialis (HL) Lesion — 66.5; 73.6 Hours — p=0.716